Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.42 |
| ▸ | EDNRB | P24530 | 5/20 | 0.40 |
| ▸ | EDNRA | P25101 | 4/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856189 | 0.91 | KMT2A (0.49) | KMT2APLA2G2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6855171 | 0.90 | KMT2A (0.49) | KMT2APLA2G2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6851204 | 0.88 | PLA2G2A (0.53) | KMT2APLA2G2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6858367 | 0.87 | KMT2A (0.47) | KMT2APLA2G2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6855746 | 0.86 | KMT2A (0.46) | KMT2APLA2G2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6858282 | 0.85 | PLA2G2A (0.49) | KMT2APLA2G2AEDNRBEDNRA | |
| SCHEMBL27598029 | 0.84 | KMT2A (0.47) | KMT2APLA2G2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6857558 | 0.83 | KMT2A (0.47) | KMT2APLA2G2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6851227 | 0.83 | PLA2G2A (0.47) | KMT2APLA2G2AEDNRBEDNRA | |
| SCHEMBL27598107 | 0.83 | KMT2A (0.44) | KMT2APLA2G2AEDNRBEDNRAMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | KMT2A 2753/4885PLA2G2A 533/4885EDNRB 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.